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Abstract
Introduction: The optimal management of coronary chronic total occlusions (CTO) has to be defined. Aim of this study is to compare percutaneous coronary intervention (PCI) vs optimal medical therapy (OMT) in patients with CTO.for CTO patients
Methods: A literature search with high specific terms was conducted using MEDLINE, EMBASE, and Web of Science to identify relevant articles. Long term MACEs (composite of cardiovascular death, acute coronary syndrome, ACS, and repeated PCI, re-PCI) was the primary endpoint, while its single components the secondary ones. 
Results: 9 studies were included (3 randomized control trial, RCT and 6 observational studies with propensity score with matching, PSWM) reporting on 6254 patients (3298 in PCI group and 2956 in OMT group). Mean Age was 63.52.6 years old, 80.8% of male gender, the mean follow-up was 38.2 months (IQR 34.5-47.7). CTO PCI was not associated with a MACE reduction (HR 1.14, 0.84-1.54) nor ACS (HR 1.67, 0,91-1.5) either re-PCI (HR 0.87, 0.67-1.99). On the other side, patients who underwent to CTO PCI had a significative CV death reduction (HR 1.91, 1.37-2.67, p<0.001) mainly driven by PSWM studies (HR 1.95, 1.39-2,73).




In patients with ischemic heart disease, the presence of chronic total occlusion (CTO) represents the most challenging clinical situation to be managed and with the lower level of established evidence (1-3).
Actually, from one side extent of coronary artery disease (CAD) was clearly related to prognosis, with a detrimental impact on short and long term survival of patients with lesions of left main (LM), of diffuse disease and of CTOs (3-5).
From the other, a revascularization driven by ischemia was often advocated for these patients, despite the neutral signal from the STICH trial and the potential, yet not largely demonstrated, impact of left ventricle remodeling (6,7). Moreover, as recently demonstrated by Sacheda et al (8) impairment of FFR (Fractional Flow Reserve) after recanalization of CTO was not related to stress echocardiography, which probably resulted not enough accurate to evaluate the burden of ischemia. 
Finally, the enormous evolution of available interventional technologies for CTO offered in the last years a wide range of potential solutions for these patients. The introduction of retrograde revascularization allowed interventional cardiologists to gain satisfactory results in terms of recanalization of occluded arteries (9-12), reducing peri-procedural complications.




	Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements (17-21) was followed to report the present paper. Two authors, independently from each other (MI and FDA) searched   Pubmed, Cochrane and Google Scholar for the following terms: “coronary revascularization” and “CTO” and “medical therapy”. 2 reviewers (MI and FDA) independently reviewed all papers, with disagreements resolved by consensus. Inclusion criteria were (i) human studies, (ii) studies comparing coronary revascularization (percutaneous or surgical) with medical therapy for CTO revascularization, (iii) follow-up longer than one year. In the case of duplicate reporting, the manuscript with the largest sample of patients was selected. 
Data abstraction.
The following data were independently abstracted by 2 reviewers (MI and FDA) on pre-specified electronic forms: authors, journal, year of publication, location of the study group, baseline, angiographic and procedural features (especially anterograde and retrograde procedures). The corresponding authors of the relevant studies were queried for required quantitative details not in the published manuscripts.  
End points.
Major cardiovascular events (MACEs, composite of cardiovascular death, MI, target vessel revascularization) were the primary end points, while its single components the secondary ones. Sensitivity analyses for MACEs, death and revascularization were performed according to design of studies (RCT vs. PSWM).
Quality study evaluation.
The quality of included studies was independently appraised by 2 reviewers (MI and FDA), with disagreements resolved by consensus. For each randomized controlled trial, we evaluated the risk of bias (low, unclear, or high) for random-sequence generation, allocation concealment, blinding of patients and physicians, blinding during assessment of follow-up, incomplete outcome evaluation, and selective reporting, in keeping with the Cochrane Collaboration approach.  
Statistical analysis.





Selected studies and baseline characteristics.
From 547 abstract, we selected 21 full-text articles fitting our selection criteria. After evaluating the full-text article, 9 studies were included whom 3 randomized control trial (RCT) and 6 observational studies with propensity score with matching (PSWM, see Supplementary Appendix references). An outline of the systematic review process is depicted in Figure 1. An overview of the RCT and PSWM studies is summarized in Supplementary Appendix Table A. 6254 patients were included in the analysis (3298 in PCI group and 2956 in OMT group). The mean follow-up was 38.2 months (IQR 34.5-47.7). Mean Age was 63.52.6 years old, 80.8% of male gender, 34.9% were diabetic and 61.2% hypertensive (see Table n.1).
Primary end-point analysis
CTO PCI compared with OMT did not show to reduce MACE (HR 1.14, 0.84-1.54, p=0.4) in general population, while there was a trend in the PSWM studies (HR 1.41, 0.94-2.12, p=0.09, see Figure n. 2). At metaregression analysis Age (slope 0.23, 0.07-0.39, p<0.01) and Hypertension (slope 0.07, 0.4-0.1, p<0.01) were associated with a lower benefit of CTO revascularization, while there was just a trend for diabetes (slope 0.02, 0.01-0.05, p=0.08).
Secondary end-point analysis
Patients who underwent to CTO PCI did not show a significative reduction of ACS (HR 1.67, 0,91-1.5, p=0.22) in the overall analysis, while there was a reduction in the PSWM studies (HR 1.52, 1.09-2.1, p=0.01, see Figure n. 3). Re-PCI were similar in the two groups (HR 0.87, 0.67-1.99). On the other side, patients in CTO PCI group had a significative CV death reduction (HR 1.91, 1.37-2.67, p<0.01) mainly driven by PSWM studies (HR 1.95, 1.39-2,73, p<0.01). At metaregression analysis any of the baseline characteristics was associated with this endpoint.
Publication bias evaluation
















Main findings of our study are:
a)	CTO PCI compared with OMT seems not to reduce MACE or re-PCI;
b)	ACS were reduced just in the PSWM studies but not in the overall analysis;
c)	patients in CTO PCI group had a significative CV death reduction;

To the best of our knowledge this is the first meta-analysis evaluating the impact of CTO PCI compared with OMT. Further, this is the first paper that included data from RCT, such as the EXPLORE trial (15), the DECISION-CTO trial recently presented at ACC 2017 congress and EURO-CTO trial exposed at EURO PCR 2017 congress.
Several meta-analysis evaluated the successful vs failed CTO PCI (3,22) showing a reduction of MACE and death. Main limitation of these analysis is the evident bias due to the different baseline characteristics that impact on the population outcomes and potential the harmful effect of a failed CTO PCI. 
From our analysis CTO PCI did not showed a significative reduction of MACE or re-PCI compared with OMT. Possible explanation for this finding is the sub-optimal success rate and the worse performance of drug eluting stents (DES) in CTO lesions (23). A recent study published by Jia H et al (23) showed that patients with CTO lesions had an unfavorable response to DES evaluated by optical coherence tomography in the acute phase as well as at the 6-month follow-up, indicating the important pathological link between the original lesion morphology underneath the stents and heterogeneous artery healing.
Similarly, ACS were similar among the two groups. This is not surprisingly because CTO PCI have no effect of on the non-CTO vessel, while potentially expose the patients to the risk of ACS on the revascularized artery.
Probably the most interesting result of our analysis is the CV death reduction.  It has been demonstrated that CTO of other than infarct-related arteries in patients hospitalized due to ACS as well as with stable coronary disease is strongly associated with higher long-term mortality than in patients without CTO (24,25). CTO in non infarct vessel have shown to be a stronger independent predictor for both early mortality and late mortality after ST-elevation myocardial infarction (STEMI) than the presence of multivessel disease without a concurrent CTO (26). This is probably due to the reduced left ventricle ejection fraction (LVEF) after STEMI and further deterioration of LVEF. A recently published sub-analysis from the COMMIT-HF Registry (27) confirmed that in patients with ischemic heart failure the presence of the CTO is related to worse long-term prognosis.  Further, these patients are generally at high risk for repeated ACS, and in case of STEMI the patients with unrevascularized CTO present a higher risk of cardiogenic shock and mortality (28).
Indeed, revascularized CTO lesion determine an increased risk of ventricular arrhythmias (29) that could partially explain this finding.
Indeed, our data show differences in the outcome between the PSWM and RCT studies. Despite RCT are considered the top in the evidence scale, in the case of CTO revascularization they suffer of several limitations mainly due to the really slow enrolment and small sample size (both EXPLORE trial and DECISION CTO trial were underpowered for slow enrolment), high crossover rate and often a low CTO PCI success rate (16). These difficulties in the enrolment underline an important selection bias that has to be taken in account, it could be speculated that the patients whom benefit the most from CTO PCI were not included in the RCT due to unacceptable quality of life or severe signs of ischemia. Due to these limitation observational studies may be more representative of the general population who refers to cardiologist for coronary CTO management.
Conclusions
CTO PCI seems not to have impact on MACEs, on the other side showed to reduce death from cardiovascular reasons.

Limitations
This is not a patient level analysis, and derive data from randomized controlled trials and from propensity score with matching observational studies. Therefore, the use of meta-regression analysis, although commonly exploited, may be viewed as hypothesis generating only and not as an analysis providing solid evidence of causal associations.
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